LexaGene Expands Brand Awareness at Key Investor Conferences
October 01 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a commercial molecular diagnostics
company selling a point-of-need highly multiplexed in-clinic PCR
system with results in approximately two hours, today announced it
will be featured at three investor relations conferences in early
October. LexaGene management will also participate in one-on-one
meetings at each conference.
“Attending these conferences allows us to update current
investors and introduce LexaGene as an investment opportunity to
future investors,” said Dr. Jack Regan, LexaGene’s CEO and Founder.
“The veterinary trade shows we attended in September made it clear
that our technology is at the forefront of innovation and is
expected to change the way diagnostics are performed in veterinary
medicine. We are excited about the increasing adoption of our
MiQLab™ system into more veterinary hospitals, where veterinarians
are interested in providing the best possible care by utilizing the
MiQLab for rapid in-clinic PCR testing for pathogens and
antimicrobial resistance.”
- BioFuture 2021, October 5-6: Top
innovators, investors and business leaders come together to
participate in discussions that will shape and transform the future
of healthcare by harnessing the power of the life sciences
ecosystem and its impact on healthcare, LexaGene will provide
insights into its open-access technology and the role it can play
in key life science verticals. Qualified investors can request
complimentary registration for the conference here.
- Lytham Partners Fall 2021 Investor
Conference taking place October 5-7. Partnering with the next
generation of innovators offering a diverse and effective platform
for connecting small cap companies with high-quality and focused
institutional investors. An audio webcast of the presentation will
be made available on LexaGene’s website. To arrange a meeting,
please contact a Lytham Partners representative at
1x1@lythampartners.com or register on their website.
- Small Cap Growth Virtual Investor
Conference, October 7. A live, interactive event where investors
are invited to ask companies questions in real-time. Virtual
Investor Conferences is the leading proprietary investor conference
series that provides an interactive forum for publicly traded
companies to meet and present directly with investors. Register at
https://www.virtualinvestorconferences.com/login-registration
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings, Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate & Media Contact:
Gail Winslow
Director of Marketing
gwinslow@lexagene.com
978.482.6237
ir@lexagene.com
800.215.1824
Investors:
Sharon Choe
Vice President
LavoieHealthScience
schoe@lavoiehealthscience.com
(857) 241-7393
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024